Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Liabilities and Shareholders Equity: 2020-2024

Historic Liabilities and Shareholders Equity for Janux Therapeutics (JANX) over the last 5 years, with Dec 2024 value amounting to $1.1 billion.

  • Janux Therapeutics' Liabilities and Shareholders Equity rose 47.44% to $1.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 billion, marking a year-over-year increase of 69.77%. This contributed to the annual value of $1.1 billion for FY2024, which is 179.05% up from last year.
  • Janux Therapeutics' Liabilities and Shareholders Equity amounted to $1.1 billion in FY2024, which was up 179.05% from $380.4 million recorded in FY2023.
  • In the past 5 years, Janux Therapeutics' Liabilities and Shareholders Equity ranged from a high of $1.1 billion in FY2024 and a low of $16.2 million during FY2020.
  • Over the past 3 years, Janux Therapeutics' median Liabilities and Shareholders Equity value was $380.4 million (recorded in 2023), while the average stood at $602.0 million.
  • In the last 5 years, Janux Therapeutics' Liabilities and Shareholders Equity spiked by 2,242.13% in 2021 and then decreased by 4.16% in 2022.
  • Over the past 5 years, Janux Therapeutics' Liabilities and Shareholders Equity (Yearly) stood at $16.2 million in 2020, then skyrocketed by 2,242.13% to $379.8 million in 2021, then decreased by 4.16% to $364.0 million in 2022, then climbed by 4.50% to $380.4 million in 2023, then surged by 179.05% to $1.1 billion in 2024.